RA Outcomes Improved in KURAMA Cohort - Report - MDSpire
Advertisement
RA Outcomes Improved in KURAMA Cohort
Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.
Clinical Report: RA Outcomes Improved in KURAMA Cohort
Overview
In a 10-year study of patients with rheumatoid arthritis, improvements in disease activity and functional disability were observed, correlating with increased use of biologic and targeted synthetic DMARDs and reduced glucocorticoid use. The study analyzed data from the Kyoto University Rheumatoid Arthritis Management Alliance cohort from 2012 to 2021.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that can lead to joint damage and disability. Effective management of RA is crucial for improving patient outcomes and quality of life. The increasing use of biologic and targeted synthetic DMARDs has been noted in treatment strategies.
Data Highlights
Year
Biologic/tsDMARD Use (%)
Glucocorticoid Use (%)
DAS28-CRP Remission (%)
CDAI Remission (%)
HAQ-DI Score
2012
30
41
-
25
0.69
2021
53
19
80
48
0.25
Key Findings
Biologic or targeted synthetic DMARD use increased from 30% to 53% over the study period.
Glucocorticoid use decreased from 41% to 19%.
Disease Activity Score 28-C-reactive protein remission reached 80% in 2021.
Clinical Disease Activity Index remission improved from 25% to 48%.
Median Health Assessment Questionnaire Disability Index scores decreased from 0.69 to 0.25.
Interleukin-6 receptor inhibitors showed improvement in some measures compared to abatacept.
Clinical Implications
The findings suggest that the increased use of biologic and targeted synthetic DMARDs may contribute to improved disease management in RA patients. Clinicians should consider these treatment modalities to enhance patient outcomes, particularly in light of the observed reductions in glucocorticoid use.
Conclusion
The KURAMA cohort study reports improvements in RA management over a decade, with changes in disease activity and functional outcomes linked to treatment strategies.
A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.
